GCL
CERE

Glazer Capital LLC’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Glazer Capital LLC’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,000
Closed -$1.64M – 181
2024
Q2 		$1.64M Buy
+40,000
New +$1.67M 0.13% 91

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Glazer Capital LLC's CERE Position: Q3 2024 in Review

Glazer Capital LLC sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 40,000 shares — an estimated $1.64M sold.

Glazer Capital LLC first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $1.64M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Glazer Capital LLC reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Glazer Capital LLC sold 40,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.64M.
  • Glazer Capital LLC first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Glazer Capital LLC's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.64M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Glazer Capital LLC's 13F filing for Q3 2024, filed 14 Nov 2024.